Open-label Trial of SUBA™-Itraconazole (SUBA-Cap) in Subjects With Basal Cell Carcinoma Nevus Syndrome (BCCNS)

NCT02354261 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

38

Enrollment

INDUSTRY

Sponsor class

Conditions

Basal Cell Carcinoma in Basal Cell Nevus Syndrome

Interventions

DRUG: SUBA-Itraconazole

Sponsor

HedgePath Pharmaceuticals, Inc.